Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JW (Cayman) Therapeutics CoJWCTF -4.38%26 Debt-to-Equity is 0.47 as of Dec. 2025, which is 422% above its 10-year median of 0.09. GuruFocus rates JWCTF with a GF Score™ of 26/100 and a GF Value™ of $0.60 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 968 Biotechnology companies, JW (Cayman) Therapeutics Co ranks worse than 74.28% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for JW (Cayman) Therapeutics Co's Debt-to-Equity or its related term are showing as below:
JWCTF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.19 Med: 0.09 Max: 0.47
Current: 0.47
During the past 8 years, the highest Debt-to-Equity Ratio of JW (Cayman) Therapeutics Co was 0.47. The lowest was -0.19. And the median was 0.09.
JWCTF's Debt-to-Equity is ranked worse than 74.28% of 968
companies
in the Biotechnology industry
Industry Median: 0.16
vs JWCTF: 0.47
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
JW (Cayman) Therapeutics Co Debt-to-Equity Related Terms
JW (Cayman) Therapeutics Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JWCTF vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JW (Cayman) Therapeutics Co Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where JW (Cayman) Therapeutics Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JW (Cayman) Therapeutics Co (JWCTF) has a Debt-to-Equity of 0.47 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on JW (Cayman) Therapeutics Co and its competitors. This is 422% above median its historical median of 0.09. According to the industry distribution chart, JW (Cayman) Therapeutics Co ranks #719 out of 968 companies in the Biotechnology industry, placing it in the top 74.3%.
Is JW (Cayman) Therapeutics Co's Debt-to-Equity too high?
JW (Cayman) Therapeutics Co's current Debt-to-Equity of 0.47 is 422% above median its 10-year median of 0.09. The Biotechnology industry median Debt-to-Equity is 0.16. JW (Cayman) Therapeutics Co's value of 0.47 is 193.8% above this industry median. Based on the distribution chart, JW (Cayman) Therapeutics Co ranks #719 out of 968 companies in the Biotechnology industry, which is below the industry midpoint. Overall, JW (Cayman) Therapeutics Co has a GF Score™ of 26/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JW (Cayman) Therapeutics Co's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, JW (Cayman) Therapeutics Co ranks #719 out of 968 companies for Debt-to-Equity. This places JW (Cayman) Therapeutics Co in the lower half of its industry. The industry median Debt-to-Equity is 0.16. JW (Cayman) Therapeutics Co's value of 0.47 is 193.8% above this benchmark. While the company's 10-year median is 0.09 vs. the industry median of 0.16, JW (Cayman) Therapeutics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 968 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JW (Cayman) Therapeutics Co's current Debt-to-Equity of 0.47 is 193.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on JW (Cayman) Therapeutics Co and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JW (Cayman) Therapeutics Co's current Debt-to-Equity is 0.47, which is 422% above median its own 10-year median of 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW (Cayman) Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co (JWCTF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.60, compared to a current price of $0.20 — trading 66.3% below its estimated fair value. The current Debt-to-Equity is 0.47, which is 422% above median its 10-year median of 0.09 and 193.8% above the Biotechnology industry median of 0.16. JW (Cayman) Therapeutics Co's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For JW (Cayman) Therapeutics Co (JWCTF), the current Debt-to-Equity is 0.47 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JW (Cayman) Therapeutics Co (JWCTF) Overvalued in 2026?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued.
The current stock price of $0.20 is trading 66.3% below its estimated GF Value™ of $0.60.
GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.
Key valuation signals for JWCTF:
Debt-to-Equity: 0.47 (422% above median its 10-year median of 0.09)
GF Value™: $0.60 vs. price of $0.20 (66.3% below fair value)
Industry Position: 193.8% above the Biotechnology median (#719 of 968)
No single metric tells the full story. See the JWCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
26GF Score
Get the complete analysis for JWCTF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JWCTF has been successfully added to your 
